Insulin-producing cells injected into a man with type 1 diabetes have survived for a month so far without the need for immune ...

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 ...

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

Sana Biotechnology Inc.'s stock soared over 200% on Wednesday, on track to mark its best day on record, amid trading volumes ...

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

Louisville basketball guard Spencer Legg is living with type 1 diabetes. Here's how he's using his diagnosis to raise ...

Samantha Semenkow, an analyst from Citi, maintained the Buy rating on Sana Biotechnology (SANA – Research Report). The associated price target ...

Mount Sinai researchers discovered that harmine, a beta cell regenerative drug, may transform alpha cells into beta cells, ...

Internal medicine and rheumatology specialist Siobhan Deshauer, MD, goes over the visual physical signs that a patient might have diabetes.